106 related articles for article (PubMed ID: 9711927)
1. Maintenance therapy with interferon alfa 2b in Hodgkin's disease.
Avilés A; Díaz-Maqueo JC; Talavera A; Nambo MJ; García EL
Leuk Lymphoma; 1998 Aug; 30(5-6):651-6. PubMed ID: 9711927
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
[TBL] [Abstract][Full Text] [Related]
3. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM
J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385
[TBL] [Abstract][Full Text] [Related]
4. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival.
Aviles A; Duque G; Talavera A; Guzman R
Leuk Lymphoma; 1996 Feb; 20(5-6):495-9. PubMed ID: 8833409
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha for maintenance of follicular lymphoma.
Baldo P; Rupolo M; Compagnoni A; Lazzarini R; Bearz A; Cannizzaro R; Spazzapan S; Truccolo I; Moja L
Cochrane Database Syst Rev; 2010 Jan; (1):CD004629. PubMed ID: 20091564
[TBL] [Abstract][Full Text] [Related]
6. Maintenance Therapy with Interferon Alfa 2b Improves Outcome in Aggressive Malignant Lymphoma.
Avilés A; Díaz-Maqueo JC; Talavera A; García EL; Nambo MJ
Hematology; 1998; 3(5):381-6. PubMed ID: 27414082
[TBL] [Abstract][Full Text] [Related]
7. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
8. Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma.
Avilés A; Neri N; Huerta-Guzmán J; Pérez F; Sotelo L
Leuk Lymphoma; 2004 Nov; 45(11):2247-51. PubMed ID: 15512813
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
Schenkein DP; Dixon P; Desforges JF; Berkman E; Erban JK; Ascensao JL; Miller KB
J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced Hodgkin's disease: EBVD versus intensive brief chemotherapy.
Avilés A; Cleto S; Neri N; Huerta-Guzmán J; Talavera A; Castañeda C; González M
Leuk Lymphoma; 2003 Aug; 44(8):1361-5. PubMed ID: 12952230
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma.
Avilés A; Díaz-Maqueo JC; García EL; Talavera A; Guzmán R
Invest New Drugs; 1992 Nov; 10(4):351-5. PubMed ID: 1487412
[TBL] [Abstract][Full Text] [Related]
12. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
14. Two dosage interferon-alpha 2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial.
Offidani M; Olivieri A; Montillo M; Rupoli S; Centurioni R; Alesiani F; Marchegiani G; Pieroni S; Catarini M; Pelliccia G; Altilia F; Leoni P
Haematologica; 1998 Jan; 83(1):40-7. PubMed ID: 9542322
[TBL] [Abstract][Full Text] [Related]
15. Interferon alfa-2b therapy in untreated early stage, B-chronic lymphocytic leukaemia patients: one-year follow-up.
Boussiotis VA; Pangalis GA
Br J Haematol; 1991 Oct; 79 Suppl 1():30-3. PubMed ID: 1931705
[TBL] [Abstract][Full Text] [Related]
16. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.
Avilés A; Neri N; Nambo JM; Huerta-Guzman J; Talavera A; Cleto S
Leuk Lymphoma; 2005 Jul; 46(7):1023-8. PubMed ID: 16019553
[TBL] [Abstract][Full Text] [Related]
17. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
18. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
19. EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease.
Angelopoulou MK; Vassilakopoulos TP; Siakantaris MP; Kontopidou FN; Boussiotis VA; Papavassiliou C; Kittas C; Pangalis GA
Leuk Lymphoma; 2000 Mar; 37(1-2):131-43. PubMed ID: 10721777
[TBL] [Abstract][Full Text] [Related]
20. ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease.
Zinzani PL; Magagnoli M; Frezza G; Barbieri E; Gherlinzoni F; Galuppi A; Bendandi M; Merla E; Albertini P; Babini L; Tura S
Leuk Lymphoma; 1999 Feb; 32(5-6):553-9. PubMed ID: 10048428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
